We take our good news where we find it. You may remember that AstraZeneca had suspended a Covid-19 vaccine trial because one participant had developed an unexplained health issue. The good news, as reported by the Associated Press, is that the trial will resume. Oxford University announced:
“The independent review process has concluded and following the recommendations of both the independent safety review committee and the U.K. regulator, the MHRA, the trials will recommence in the U.K.,” it said.
